Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver condition affecting up to a quarter of the global population. It is characterized by accumulation of fat in the liver, not caused by excessive alcohol consumption. This article provides a concise overview of its causes, symptoms, and modern therapeutic approaches.
The exact cause of NAFLD remains uncertain. However, it is commonly associated with metabolic syndrome, which includes conditions such as obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and certain lifestyle factors, such as poor diet and lack of physical activity, also contribute to the development of NAFLD.
NAFLD is often asymptomatic in its early stages, making it difficult to diagnose. When symptoms do occur, they may include fatigue, discomfort in the upper right abdomen, and unexplained weight loss. In more advanced stages, NAFLD can progress to non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer, presenting more severe symptoms.
There is currently no specific drug approved for NAFLD. The primary approach to management is lifestyle modification, including diet changes and increased physical activity. Pharmacological interventions are used to manage associated conditions, such as diabetes and hyperlipidemia. Emerging therapies, including novel anti-diabetic drugs and agents targeting inflammation and fibrosis, are under investigation.
NAFLD is a complex and prevalent condition, often associated with metabolic syndrome. Despite its asymptomatic nature in early stages, it can lead to serious liver complications if left untreated. While lifestyle modification remains the cornerstone of management, the search for effective drug therapies continues. Understanding the causes and symptoms of NAFLD is crucial for early detection and intervention, ultimately improving patient outcomes.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation